(Total Views: 465)
Posted On: 01/16/2020 11:36:54 AM
Post# of 155165
Re: thriftycents #15164
Thriftycents,
Valid question. The truth is we don't know. A recent article which analyzed 27 representative products (actually 32 but 5 where not included in the final report) yielded the following results:
https://aspe.hhs.gov/system/files/pdf/259996/...BDrugs.pdf
U.S. prices are lower: For two products (Gammagard and Soliris), U.S. prices were lower than the average international price ratio
Prices are similar: For five products, while the U.S. price is higher, it is within 20 percent of the international price (Gamunex-c & Gammaked, Keytruda , Privigen, Remicade, and Velcade).
U.S. prices are higher: For the remaining 20 products, U.S. prices exceed the average international price by more than 20 percent. This includes three products (Lucentis, Prolia & Xgeva, and Treanda) with U.S. prices more than four times the international average.
We need to differentiate as well HIV and Oncology pricing. If the HIV prices are moderate I would not foresee a large difference in pricing in high-income countries. This is a different story down the road for low-income ones where generics are prevalent. But this is something that will need to be addressed somewhat latter.
As the volumes for EU and CHINA will be obviously very large, I think CYDY could negotiate a good pricing (meaning slightly lower than Vyera's USA) when making a commercialization deal.
All imho
Valid question. The truth is we don't know. A recent article which analyzed 27 representative products (actually 32 but 5 where not included in the final report) yielded the following results:
https://aspe.hhs.gov/system/files/pdf/259996/...BDrugs.pdf
U.S. prices are lower: For two products (Gammagard and Soliris), U.S. prices were lower than the average international price ratio
Prices are similar: For five products, while the U.S. price is higher, it is within 20 percent of the international price (Gamunex-c & Gammaked, Keytruda , Privigen, Remicade, and Velcade).
U.S. prices are higher: For the remaining 20 products, U.S. prices exceed the average international price by more than 20 percent. This includes three products (Lucentis, Prolia & Xgeva, and Treanda) with U.S. prices more than four times the international average.
We need to differentiate as well HIV and Oncology pricing. If the HIV prices are moderate I would not foresee a large difference in pricing in high-income countries. This is a different story down the road for low-income ones where generics are prevalent. But this is something that will need to be addressed somewhat latter.
As the volumes for EU and CHINA will be obviously very large, I think CYDY could negotiate a good pricing (meaning slightly lower than Vyera's USA) when making a commercialization deal.
All imho
(2)
(0)
